newsfilter
← Latest News
GlobeNewswire·

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and